CURIS, INC. Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal)
CURIS, INC. (CRIS) reported Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal · last filed 2022-02-24
- CURIS, INC. debt securities, available-for-sale, change in present value, expense (reversal) for fiscal 2021 was $0.00.
- CURIS, INC. debt securities, available-for-sale, change in present value, expense (reversal) for fiscal 2020 was $0.00.
- CURIS, INC. debt securities, available-for-sale, change in present value, expense (reversal) for fiscal 2019 was $0.00.
| Period end | Debt Securities, Available-for-sale, Change in Present Value, Expense (Reversal) 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |